ASH 2023 | CAR-T therapy in AML: why has there been a lack of success?
Chong Chyn Chua, MBBS, FRACP, FRCPA, The Alfred Hospital and Monash University, Melbourne, Australia, addresses the challenges associated with CAR-T therapy in acute myeloid leukemia (AML). In contrast to its success in treating myeloma and lymphoma, AML faces obstacles due to the absence of a clear target antigen and concerns regarding T-cell activation. Dr Chua suggests that CAR-T therapy in AML might be most beneficial as a bridging therapy but recognizes this is not cost-effective. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
BMS, Astra Zeneca, AbbVie, Otsuka: Speakers Bureau; AbbVie, Pfizer, Sumitomo Pharma Oncology: Consultancy.
